US-based Asklepios BioPharmaceutical, Inc. (AskBio), a wholly owned and independently operated subsidiary of Germnay-based Bayer AG, announced on Thursday that it has named Gustavo Pesquin as its new chief executive officer (CEO) effective 11 March 2023.
Pesquin has served as chief commercial officer at Amneal Pharmaceuticals, Inc. He has over 10 years of experience at Sanofi, where he served in leadership roles of increasing responsibility, including North America head for General Medicines and global head of the Diabetes and Cardiovascular Franchise. He has held the position of regional head, general manager, sales head and strategy head roles at Abbott and Pfizer; brand management roles at Procter & Gamble; and consultant roles with Boston Consulting Group.
Pesquin holds an MBA with a concentration in Management and Strategy, Finance and Accounting from Kellogg School of Management at Northwestern University and a bachelor's degree in Public and Business Administration from Universidad Nacional de Cuyo in Argentina.
Clario partners with AWS on advancing clinical data analysis with generative AI
Langhua Pharmaceutical passes US FDA's on-site inspection
Abbott receives CE Mark for Volt Pulsed Field Ablation System to treat atrial fibrillation
Ionis announces partnership expansion with Sobi for global olezarsen commercialisation
BioCardia secures Japanese patent for Helix biotherapeutic delivery system
Doer Bio completes DR10624phase two clinical study enrolment
Kancera and Recardio sign letter of intent for licensing agreement
Novo Nordisk launches NovoCare Pharmacy to reduce Wegovy costs and expand access
Redx Pharma reports positive Phase 1 results for RXC008 in fibrostenotic Crohn's disease
Hims & Hers acquires Trybe Labs to expand at-home testing capabilities
TriNetX and Fujitsu form joint venture to enhance clinical research in Japan
Novartis to acquire Anthos Therapeutics in USD925m deal to expand cardiovascular pipeline
BrainCool secures market approval for BrainCool System in Malaysia
Roche's blood test measuring Lp(a) in molar units receives US FDA 510(k) approval